The use of decomposition methods in real-world treatment benefits evaluation for patients with type 2 diabetes initiating different injectable therapies: findings from the Initiator study by Brekke, Lee et al.




Sanofi US. M. Grabn
and O. Baser are em
E-mail: lee.brekk
* Address correspojournal homepage: www.elsevier .com/ locate / jva lThe Use of Decomposition Methods in Real-World Treatment
Benefits Evaluation for Patients with Type 2 Diabetes Initiating
Different Injectable Therapies: Findings from the INITIATOR
Study
Lee Brekke, PhD1,*, Erin Buysman, MS1, Michael Grabner, PhD2, Xuehua Ke, PhD2, Lin Xie, MS3,
Onur Baser, PhD3,4,5, Wenhui Wei, PhD6
1Optum, Eden Prairie, MN, USA; 2HealthCore, Inc., Wilmington, DE, USA; 3STATinMED Research, Ann Arbor, MI, USA; 4University
of Michigan, Ann Arbor, MI, USA; 5School of Economy, Administrative and Social Sciences, MEF University, Istanbul, Turkey; 6Sanofi
US, Bridgewater, NJ, USAA B S T R A C TBackground: Determining characteristics of patients likely to benefit
from a particular treatment could help physicians set personalized
targets. Objectives: To use decomposition methodology on real-world
data to identify the relative contributions of treatment effects and
patients’ baseline characteristics. Methods: Decomposition analyses
were performed on data from the Initiation of New Injectable Treat-
ment Introduced after Antidiabetic Therapy with Oral-only Regimens
(INITIATOR) study, a real-world study of patients with type 2 diabetes
started on insulin glargine (GLA) or liraglutide (LIRA). These analyses
investigated relative contributions of differences in baseline character-
istics and treatment effects to observed differences in 1-year outcomes
for reduction in glycated hemoglobin A1c (HbA1c) and treatment persis-
tence. Results: The greater HbA1c reduction seen with GLA compared
with LIRA (1.39% vs. 0.74%) was primarily due to differences in
baseline characteristics (HbA1c and endocrinologist as prescribing
physician; P o 0.050). Patients with baseline HbA1c of 9.0% or more or
evidence of diagnosis codes related to mental illness achieved
greater HbA1c reductions with GLA, whereas patients with baselineee front matter Copyright & 2017, International S
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ndence to: Lee Brekke, Optum, 11000 Optum Circlepolypharmacy (6–10 classes) or hypogylcemia achieved greater reduc-
tions with LIRA. Decomposition analyses also showed that the higher
persistence seen with GLA (65% vs. 49%) was mainly caused by differ-
ences in treatment effects (P o 0.001). Patients 65 years and older, those
with HbA1c of 9.0% or more, those taking three oral antidiabetes
drugs, and those with polypharmacy of more than 10 classes had
higher persistence with GLA; patients 18 to 39 years and those with
HbA1c of 7.0% to less than 8.0% had higher persistence with LIRA.
Conclusions: Although decomposition does not demonstrate causal
relationships, this method could be useful for examining the source
of differences in outcomes between treatments in a real-world setting
and could help physicians identify patients likely to respond to a
particular treatment.
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Recently published guidelines on the management of type 2
diabetes (T2D) recommend that physicians set targets for glyce-
mic control that are personalized to each individual patient. The
target level of glycated hemoglobin A1c (HbA1c) should be prac-
tical and achievable for each patient, taking into account factors
such as medical history and personal circumstances [1–3].
The choice of HbA1c target is made easier if the physician
knows that a patient is likely to benefit from a particular drug
therapy. Comparative effectiveness research based on observa-
tional data helps to identify effective treatments, and a key
component of comparative effectiveness research is to take intoaccount the heterogeneity of the treatment response (i.e., why
certain patients respond better than others when given the same
treatment) [4]. Various regression methods are commonly used in
observational studies to estimate the average treatment response
(e.g., change in HbA1c) while adjusting for imbalance in baseline
characteristics (e.g., age, sex, and comorbid conditions) between
the treated and untreated groups or between two treatment
groups. This is most commonly done by using the treatment
response as the dependent variable and including treatment (e.g.,
treatment 1 or 2) and the other covariates (i.e., baseline character-
istics) as independent variables. The resulting regression coef-
ficient (i.e., beta) for the treatment term then provides
an estimate of the adjusted overall treatment effectociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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methods have well-known limitations including possible bias
from unmeasured confounders and model mis-specification, but
are widely used.
Standard regression methods can be expanded to estimate
heterogeneity of the treatment response by including interac-
tions between the treatment variable and the other covariates
that may affect the response. The regression coefficient of a
particular treatment-covariate interaction is then an estimate of
the effect of the covariate on treatment response. Although a
valid approach, the many interaction terms used in this method
may be difficult to interpret. The impact of the interaction terms
on a specific population is often particularly difficult to under-
stand from the model results without further analysis. These
issues can make exploring heterogeneity of response through
interactions challenging.
“Decomposition” is an alternative regression method for
comparing two groups that, in our context, can be used for
estimating the heterogeneity of treatment response while avoid-
ing the use of treatment interaction terms. It also directly gives
estimates of the average effect of each covariate on the treatment
response within the study population, which is useful for inter-
pretation. This methodology is often called the Blinder-Oaxaca
decomposition, named after the developers of the technique as
originally applied to wage discrimination [5,6]. Decomposition
can be applied both to continuous and categorical outcomes and
to linear and nonlinear regression models [5–9]. In decomposi-
tion, instead of the interaction terms a stratified regression is
performed; that is, separate regressions are estimated for treat-
ment 1 and treatment 2 groups. In both models, the dependent
variable is again the response variable (e.g., change in HbA1c) and
both regressions have the same set of independent covariates
that may affect the response. But there are no “treatment” terms
in the regressions because the regressions are all either on the
treatment 1 subpopulation or on the treatment 2 subpopulation.
The information that would be contained in the interaction
terms of a single regression model is still present in the decom-
position models but it is now contained in the differences in the
regression coefficients between the two models—the treatment 1
model versus the treatment 2 model. To make that information
explicit, the decomposition method rearranges the regression
equations to separate out two components of the difference in
response between the treatment 1 and treatment 2 groups: a
component coming from differences in baseline characteristics
(often called the “explained” part in the decomposition literature
because it is explained by observed differences in the baseline
characteristics) and a component coming from differences in the
regression coefficients (often called the “unexplained” part in the
decomposition literature because it is not explained by observed
differences in the baseline characteristics). In our context, in
which one regression is on treatment 1 subjects and the other is
on treatment 2 subjects, the unexplained part is the treatment
effect that would come from the interactions with treatment in
the more standard single regression approach but evaluated
using the mean covariates from just one of the populations
(e.g., population 2) [10]. In particular, if the treatment effects
vanish in the standard regression method (i.e., there are no
differences between the treatment coefficients), then the unex-
plained part will also vanish. Thus, the terms “unexplained part”
and “treatment effects” are used interchangeably in this article.
As a regression-based method, however, the decomposition
method has the same possibility of biases from mis-
specification and unmeasured confounders as other regression
techniques and thus one must be similarly cautious in the
interpretation of the treatment effects coming from the models
—they indicate relationships in the current data and thus
warrant further investigation but they may or may notcorrespond to true causal relationships. The method relies on
the treatment 1 regression results giving an accurate description
when applied to the treatment 2 population and vice versa. This
may be particularly problematic if the covariate distributions in
the two populations do not have a similar range of values, in
which case more extrapolation is required. Additional details
about the decomposition method are given in the Methods
section.
An opportunity to apply decomposition analysis to real-
world data from the field of diabetes care recently arose: the
26-week, randomized controlled Liraglutide Effect and Action
in Diabetes 5 (LEAD-5) trial indicated that when added to
metformin and sulfonylurea, treatment with liraglutide (LIRA;
a once-daily glucagon-like peptide 1 receptor agonist) resulted
in significant improvements in glycemic control and body
weight compared with insulin glargine (GLA) [11]. LIRA
reduced HbA1c significantly compared with GLA (1.33% vs.
1.09%; P ¼ 0.0015) and was also associated with greater weight
loss (treatment difference 3.43 kg; P o 0.0001) as well as
with higher frequency of gastro-intestinal adverse events. The
Initiation of New Injectable Treatment Introduced after Anti-
diabetic Therapy with Oral-only Regimens (INITIATOR) study
was designed and conducted to see whether this finding from
the LEAD-5 study translated into the real-world setting. This
large, observational, longitudinal study assessed the character-
istics and 1-year outcomes of patients with T2D started on
injectable therapy with either GLA (administered via prefilled
disposable pen) or LIRA [12,13].
The objective of this present analysis was to use decomposi-
tion methodology on real-world data from the INITIATOR study
to identify the relative contributions of treatment effects and
patients’ baseline characteristics to observed differences in
response to the two treatments. Response was assessed in two
ways: change in HbA1c and treatment persistence.Methods
Study Design and Patients
Commercial health care claims data linked to laboratory results
were extracted from two large, independent administrative
claims databases associated with OptumTM and HealthCore® in
the United States. Data from these two databases include medical
claims, pharmacy claims, and laboratory results; both databases
have been used in hundreds of peer-reviewed publications across
multiple therapeutic areas. Data were obtained for all patients
with T2D 18 years and older, previously on oral antidiabetes
drugs (OADs) only, with a baseline HbA1c of 7.0% or more, and
who initiated (using a 6-month washout period) either GLA
(administered via prefilled disposable pen) or LIRA between April
1, 2010, and March 31, 2012. The administrative claims and
laboratory results were complemented by information from
medical charts; patients were excluded if a medical chart was
not available. The index date was defined as the earliest pre-
scription fill date. T2D was defined as having one or more
inpatient/emergency department medical claim or two or more
ambulatory medical claims (Z30 days apart) with a primary or
secondary International Classification of Diseases, Ninth Revision,
Clinical Modification code for T2D (250.x0 or 250.x2) [14].
In addition, patients included in the study were required to
have one or more pharmacy claim for an OAD during the baseline
period and to have had continuous health care coverage during
the 6 months before (baseline) and the 12 months after initiation
(follow-up) (Fig. 1).
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Fig. 1 – Attrition diagrams for the patients from the (A) Optum and (B) HealthCore databases. GLA, glargine; HbA1c, glycated
hemoglobin A1c; LIRA, liraglutide.
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Change in HbA1c between baseline and follow-up was calculated
for all patients with available results. The HbA1c measurement
closest to the index date (but not later than 15 days after the
index date) was chosen as the baseline value; the
follow-up value was chosen as the measurement closest to the
index date plus 359 days (1-year follow-up) and within the range
of index date plus 269 days through index date plus 449 days
(90 days before and after the end of 1-year follow-up). Treatment
persistence was defined as the percentage of patients remaining
on therapy without discontinuation for the duration of the 1-year
follow-up period. Study medication was considered to have been
discontinued if a prescription was not refilled within the
expected time of medication coverage (the 90th percentile of
time between the first and second prescriptions among patients
with more than one prescription, stratified by the metric quantity
supplied and irrespective of postindex eligibility). Patients who
restarted their index medication after discontinuing during the
follow-up period were considered nonpersistent [12,13,15].
Statistical Analyses
Baseline variables were compared between GLA and LIRA cohorts
using Student t tests or χ2 tests, depending on the distribution of
the measure.To model the outcomes for the decomposition analyses,
regressions adjusted by baseline covariates were run separately
on each of the two cohorts (linear regression for HbA1c reduc-
tion and logistic regression for treatment persistence). Then,
the following equation was used, where subscript 1 denotes the


















where Y1 and Y2 are average predicted values, ΣXiβj denotes
the sum of covariates from population i (Xi) times beta
coefficients from regression of population j (βj), and F[Z] is
a nonlinear function that depends on the type of model
being used. For change in HbA1c, where ordinary least-
squares regression was used, F[Z] ¼ Z. For persistence,
where logistic regression was used, F[Z] was the inverse
logistic function. The bar over the ΣXiβj terms denotes the
average over population i.
The equation describes how the differences in outcomes
between the two groups ðY1  Y2) are accounted for by explained





















Thus, the explained part is the change in average predicted
values when the covariate values are changed from observed
population 1 values to observed population 2 values but the
regression coefficients (betas) are held fixed (with values from the
population 1 regression). The unexplained part is the change in
average predicted values when the covariate values are held fixed
(with values from population 2) but the regression coefficients are
changed from the values from the population 1 regression to the
values from the population 2 regression. The unexplained part is
thus the treatment effect as applied to population 2. The “overall”
explained and unexplained parts can be further broken down into
individual terms because of particular covariates. These are
called “detailed” explained and unexplained decompositions.
For linear regression the detailed decompositions are the indi-
vidual terms from the ΣXiβj sums corresponding to each partic-
ular covariate, that is, β1(x̄1  x̄2) for explained decomposition and
x̄2(β1  β2) for unexplained decomposition. For the logistic
regression, the detailed decompositions were estimated using
the method given by Yun [16].
The baseline variables included as independent variables in
the regressions were age, sex, US region, HbA1c, body mass index,
OAD class count, Quan-modified Charlson comorbidity index
score, specialty of index prescribing physician, any diabetes-
related inpatient hospitalization, any diabetes-related emergency
department visit, number of ambulatory visits, hypertension,
hyperlipidemia, neuropathy, retinopathy, mental illness, poly-
pharmacy as the number of therapeutic classes of medications
prescribed (0–5, 6–10, or 10þ), any hypoglycemia event, and a flag
for notes in the medical chart of improving weight control as the
reason for initiating index therapy.
Data were analyzed using SAS 9.3 software (SAS Institute, Inc.,
Cary, NC) [17]. The oaxaca package for the STATA software
system (StataCorp LP, College Station, TX) [18] was used to
run all decomposition modeling and analyses (oaxaca was
originally written by Jann [7], updated version August 2011).
(See Ref. [7] and oaxaca documentation for details about how to
run the package.)Results
Demographic and Clinical Characteristics of the INITIATOR
Patient Population
A total of 3773 patients with T2D were included in this analysis
(Fig. 1). Overall, women comprised 43.9% of the patient popula-
tion, mean age was 52.5 years, and the mean number of OADs
filled at baseline was 2. The number of patients in the final
sample who had complete data for follow-up HbA1c and all
covariates that were included in the analysis of follow-up HbA1c
was 2166 (57.4%).
The two groups showed some differences in baseline charac-
teristics (Table 1). Patients in the GLA prefilled disposable-pen
group had a higher mean burden of comorbidity (as shown by the
Quan-modified Charlson comorbidity index score), higher mean
HbA1c, and lower mean body weight; in addition, a greater
proportion of this group was male. Patients in the LIRA group
had a higher mean body weight and were more likely to have
“improve weight control” recorded by their physician as a reason
for treatment initiation (17.8% in the LIRA group compared with
3.5% in the GLA group) (P o 0.001).HbA1c: Main Findings and Decomposition
The final sample with complete information on all covariates of
interest had 2166 patients for the decomposition analysis of the
“HbA1c changes” outcome. There was a significantly greater
1-year reduction in HbA1c in patients in the GLA prefilled
disposable-pen group (1.39%) compared with patients in the
LIRA group (0.74%). Overall, the decomposition analysis
revealed that the difference between the two groups (0.65%)
was largely due to the differences in baseline population charac-
teristics (the explained part: 0.73%; P o 0.001). This was offset
by a small and nonsignificant effect caused by differences in
treatment effects (the unexplained part: 0.09%) (Table 2).
Detailed decomposition analysis of the explained part of the
HbA1c change identified the following significant baseline factors:1. Baseline HbA1c of 7.0% to less than 8.0%: This accounted for a
difference of 0.191 (P ¼ 0.001), which is 26.2% of the explained
difference and 29.6% of the total difference between the two
groups. This difference in change in HbA1c is driven by the
higher proportion of baseline HbA1c of 7.0% to less than 8.0% in
the LIRA group (37.2%) compared with the GLA group (15.5%).
Higher proportions of baseline HbA1c of 7.0% to less than 8.0%
are associated with smaller reductions in HbA1c.2. Baseline HbA1c of 8.0% to less than 9.0%: This accounted for a
difference of 0.037 (P ¼ 0.003), which is 5.1% of the explained
difference and 5.8% of the total difference between the two
groups. This difference in change in HbA1c is driven by the
higher proportion of baseline HbA1c of 8.0% to less than 9.0%
in the LIRA group (29.8%) compared with the GLA group
(20.7%). Higher proportions of baseline HbA1c of 8.0% to less
than 9.0% are associated with smaller reductions in HbA1c.3. Baseline HbA1c of 9.0% or more: This accounted for a difference
of 0.398 (P ¼ 0.001), which is 54.5% of the explained difference
and 61.7% of the total difference between the two groups. This
difference in change in HbA1c is driven by the lower proportion
of baseline HbA1c of 9.0% or more in the LIRA group (33.0%)
compared with the GLA group (63.8%). Higher proportions of
baseline HbA1c of 9.0% or more are associated with larger HbA1c
reductions. On the basis of the decomposition analyses of
different baseline HbA1c groups, the results showed that lower
levels of baseline HbA1c are associated with smaller reductions
in HbA1c.4. Having an endocrinologist as the index prescribing physician
(as opposed to a primary care physician or a health care
professional from another specialty): This accounted for a
difference of 0.028 (P ¼ 0.014), which is 3.9% of the explained
difference and 4.4% of the total difference between the two
groups (the negative sign indicates that this contributed
toward making the total difference between groups smaller
rather than larger). This difference in change in HbA1c is
driven by the higher proportion of endocrinologists in the
LIRA group (26.9%) compared with the GLA group (18.4%).
Higher proportions of endocrinologists are associated with
greater reductions in HbA1c.5. Detailed decomposition analysis of the (overall nonsignifi-
cant) unexplained part of the HbA1c change (the part of
the change attributed to differences in treatment effects
rather than to differences in baseline characteristics) showed
that patients with baseline HbA1c of 9.0% or more or who had
diagnosis codes of mental illness achieved greater 1-year
reductions in HbA1c when taking GLA than when taking LIRA.
In contrast, patients with baseline polypharmacy of 6 to 10
classes or any hypogylcemia achieved greater 1-year reduc-
tions in HbA1c when taking LIRA than when taking GLA
(Fig. 2).
Table 1 – Baseline demographic and clinical characteristics of patients in the INITIATOR study (N ¼ 3773).
Characteristic GLA (n ¼ 1965) LIRA (n ¼ 1808) P value
Age (y), mean  SD 53.0  8.80 51.9  8.76 o0.0001
Sex, n (%)*
Male 1143 (58.2) 975 (53.9) 0.0087
Female 822 (41.8) 833 (46.1) 0.0087
Duration of disease (y), mean  SD 7.33  7.60 6.57  5.52 0.1011
Health plan type, n (%)*
HMO 327 (16.6) 265 (14.7) 0.0941
POS 976 (49.7) 890 (49.2) 0.7854
PPO 517 (26.3) 495 (27.4) 0.4595
Other 145 (7.4) 158 (8.7) 0.1247
Body weight (kg), mean  SD 101.0  23.3 110.9  24.1 o0.0001
HbA1c (%), mean  SD 9.97  1.94 8.76  1.52 o0.0001
Prescribing physician, n (%)*
Endocrinologist 367 (18.7) 454 (25.1) o0.0001
Primary care physician 1367 (69.6) 1157 (64.0) 0.0003
OADs, n (%)*
Metformin 1559 (79.3) 1506 (83.3) 0.0019
DPP-4 inhibitors 762 (38.8) 723 (40.0) 0.4471
Meglitinides 57 (2.9) 51 (2.8) 0.8830
Sulfonylureas 1211 (61.6) 954 (52.8) o0.0001
Thiazolidinediones 613 (31.2) 589 (32.6) 0.3629
Alpha-glucosidase inhibitors 16 (0.8) 8 (0.4) 0.1513
Number of OADs per patient, mean  SD 2.15  0.90 2.12  0.91 0.3474
Comorbidities, n (%)*
Myocardial infarction 43 (2.2) 22 (1.2) 0.0220
Congestive heart failure 68 (3.5) 40 (2.2) 0.0216
Renal disease 117 (6.0) 64 (3.5) 0.0005
Hypoglycemia 46 (2.3) 32 (1.8) 0.2181
Neuropathy 158 (8.0) 118 (6.5) 0.0744
Nephropathy 74 (3.8) 67 (3.7) 0.9225
Retinopathy 152 (7.7) 100 (5.5) 0.0067
Obesity† 1119 (71.2) 1248 (86.8) o0.0001
Quan-modified CCI, mean  SD 0.86  1.48 0.63  1.17 o0.0001
Weight control as the reason for initiating index therapy, n (%)* 68 (3.5) 322 (17.8) o0.0001
Total diabetes-related costs ($), mean  SD per patient 3260  11,894 2084  4513 o0.0001
BMI, body mass index; CCI, Charlson comorbidity index; DPP-4, dipeptidyl peptidase 4; GLA, glargine; HbA1c, glycated hemoglobin A1c; HMO,
health maintenance organization; LIRA, liraglutide; POS, point of service; PPO, preferred provider organization; OADs, oral antidiabetes drugs.
* Dichotomous or categorical variables were compared using χ2 tests (continuous variables were compared using Student t tests).
† Obesity is defined as BMI Z 30 kg/m2 in the subset of patients with BMI available (n ¼ 1572 for GLA and n ¼ 1438 for LIRA).
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The final sample with complete information on all covariates of
interest consisted of 3010 patients for the decomposition
analysis of the treatment persistence outcome. Treatment
persistence at 1 year was found to be significantly higher in
the GLA group (64.8%) compared with the LIRA group (48.7%).










P value o0.001 o0.001 o0.001
GLA, glargine; HbA1c, glycated hemoglobin A1c; LIRA, liraglutide.between the two groups (16.1%) was largely due to differences
in treatment effects (the unexplained part: 17.9%; P o 0.001).
This was offset by a small and nonsignificant effect caused by
differences in baseline characteristics (the explained part:
1.8%) (Table 3).
Detailed decomposition analysis of the explained part of the
difference in persistence between the two groups identified












Fig. 2 – Contribution of treatment effects to reductions in
HbA1c. Other baseline factors adjusted in the decomposition
analysis were age, sex, region, other HbA1c categories, body
mass index, other OAD count categories, Charlson
comorbidity index, comorbid conditions, prescriber of index
drug, health care resource utilization, polypharmacy,
hypoglycemia, and use of index drug for body weight
control. GLA, glargine; HbA1c, glycated hemoglobin A1c;
LIRA, liraglutide; OAD, oral antidiabetes drug.
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persistence rate (P ¼ 0.018), which is 4.06% of the total differ-
ence between the groups.
Detailed decomposition analysis of the unexplained part of
the difference in persistence showed that patients who were
older (aged Z65 years), and those with baseline HbA1c of 9.0% or
more, an OAD class count of 3, or with polypharmacy of more
than 10 classes, had a higher rate of persistence with GLA
compared with similar patients taking LIRA. Patients who were
younger (aged 18–39 years), and those with baseline HbA1c of 7.0%
to less than 8.0%, had a higher rate of persistence with LIRA than
with GLA (Fig. 3).Discussion
The application of decomposition analysis to real-world data
from the INITIATOR study suggested that differences in patients’
baseline characteristics contributed most to the observed 1-year
difference in effects on HbA1c between the GLA and LIRA groups.
Differences in treatment effects, however, appeared to contribute
most to the observed difference in 1-year persistence between
the two groups.
If verified by additional research, both these main findings
could have potential implications for the future management of
patients with T2D in terms of the personalized selection of
treatment for individual patients. For HbA1c control, patients
with a high baseline HbA1c and patients with evidence of
diagnosis codes related to mental illness might benefit more
from taking GLA to achieve greater 1-year reductions compared
with taking LIRA. In contrast, patients with polypharmacy (6–10
classes) or with any baseline hypoglycemia might benefit more
from taking LIRA to achieve greater 1-year reductions in HbA1c
rather than taking GLA.
For improving treatment persistence, care for patients 65
years or older, those with a high baseline HbA1c, those taking
three different classes of OADs, and those with polypharmacy(410 classes) might be personalized to achieve a higher
1-year rate of treatment persistence by recommending GLA.
Patients aged 18 to 39 years and those with baseline HbA1c of
7.0% to less than 8.0% might be personalized to achieve a higher
1-year rate of persistence by taking LIRA.
This study suggests that decomposition can usefully be
applied to real-world data in the clinical setting to examine the
source of differences in outcomes between two pharmaceutical
treatments. Blinder-Oaxaca decomposition is an established
method for investigating differences between groups. A review
of published articles reveals that it has been used, among others,
to identify factors that contribute to the gap in nutrition between
poor and nonpoor children in India [19], the poorer health status
of women compared with men [20], sex differences in disability
in older adults [21], inequalities in health between indigenous
and nonindigenous populations in India [22], and different
uptake rates for cervical screening with Papanicolaou test in
Canada and the United States [23].
Decomposition has also been used to investigate factors
contributing to economic inequalities in visual impairment [24]
and eye care utilization [25] in Iran, infant mortality in Iran [26],
differences in the prevalence and severity of chronic health
conditions in Spain [27], differences in health care use among
Mexican immigrants in California [28], racial disparities in access
to preventive dental care in South Africa [29], differences in the
costs of health care for gastroesophageal reflux disease among
patients with chronic obstructive pulmonary disease [30], and
racial disparities in access to weight-related counseling during
preventive health care visits in the United States [31]. Decom-
position has also been previously suggested for use in comparing
pharmaceutical treatments, although it is not yet widely used
[10,32]. One particular advantage of this method is that it
quantifies the proportion that each covariate contributes to the
differences in the observed outcomes. This representation of the
results may improve decision making in personalized selection of
treatment and help patients realize greater treatment effective-
ness on the basis of their individual conditions.
Limitations of the present study include the fact that it is
retrospective and observational. This means that the analyses
may be subject to selection bias and confounding, and that it is
difficult to establish the causality of drug effects on the observed
outcomes. The data used in the analyses were obtained from a
managed care population of patients with T2D and required the
availability of complete data for the analysis; this may not
necessarily be representative of patients with T2D overall, so
caution is needed before extrapolating the findings to a wider
population. When comparing the baseline demographic charac-
teristics of the population with data for follow-up HbA1c and all
covariates that were included in the follow-up HbA1c analysis
with those of patients who were not included in the analysis,
some differences were observed. Even though these differences
reach statistical significance, one could argue about the clinical
relevance of the differences (see Appendix Table 1 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2017.05.019).
Decomposition, being a regression-based method, can suffer
bias from unmeasured confounders and mis-specification of the
model. The exact decomposition is also not unique, depending on
the choice of reference group and the choice of method for
detailed decomposition in the nonlinear model case. Different
choices may, in some cases, slightly alter one’s interpretation of
the results. The decomposition method uses the same informa-
tion as is present in a single regression including interactions of
treatment with all other covariates. The exact same beta coef-
ficients can in fact be calculated using either the two stratified
models or the single interacting model. In that sense the two
methods are equivalent. There can be some differences in
Table 3 – Treatment persistence: Results of overall decomposition analysis at 1 y (N ¼ 3010).












Mean persistence (%) 64.8 48.7 16.1 1.8 17.9
P value o0.001 o0.001 o0.001 0.215 o0.001
GLA, glargine; LIRA, liraglutide.
V A L U E I N H E A L T H 2 0 ( 2 0 1 7 ) 1 2 5 2 – 1 2 5 91258standard errors calculated with standard statistical packages in
the two methods but because the coefficients themselves match
for any sample, bootstrapping techniques, for example, applied to
both models appear guaranteed to produce identical standard
errors. Given this equivalence, the stratification in decomposition
itself does not appear to mitigate multicollinearity concerns
arising from the many interaction terms in the interacting single
model, although there are some contradictory statements in the
literature [10,32]. Either method requires sufficient sample size
and covariate variation within cohorts to accurately estimate all
the required terms in both cohorts. There must also be sufficient
covariate distribution overlap with good model fit so that the beta
coefficients from one cohort can be used to accurately represent
the outcome based on the covariate distributions of the other
cohort.
Also, we used a specific empirical method for calculating persis-
tence, and it is unknown whether other methods would have
different results. The expected time of medication coverage is
defined in our article as the 90th percentile of time between the firstFig. 3 – Contribution of treatment effects to persistence.
Other baseline factors adjusted in the decomposition
analysis were other age categories, sex, region, other HbA1c
categories, body mass index, other OAD count categories,
Charlson comorbidity index, comorbid conditions,
prescriber of index drug, health care resource utilization,
polypharmacy, hypoglycemia, use of index drug for body
weight control, and patient-paid amount for index therapy.
GLA, glargine; HbA1c, glycated hemoglobin A1c; LIRA,
liraglutide; OAD, oral antidiabetes drug.and second prescriptions among patients with more than one
prescription, stratified by the metric quantity supplied and irrespec-
tive of postindex eligibility. This percentile of time was then used to
determine whether a given patient was considered persistent or not.
Sensitivity analyses were conducted using the 75th and the 95th
percentiles to calculate the expected time of medication coverage,
but were analyzed only descriptively because results were consistent
using the three different percentiles in the descriptive analysis. The
baseline characteristics of patients included in the cohort with data
for all covariates included in the follow-up persistence analysis are
compared with those of patients not included in this sample in
Appendix Table 2 in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2017.05.019.
Finally, pharmacy claims data were used to estimate the level
of persistence with therapy. These data show that prescriptions
have been filled, but not that the therapies were actually taken as
prescribed; this remains a potential source of error. Another
source is the reliance on health care claims data, which are
always potentially subject to coding errors on data entry. Our
study, however, linked the claims data to medical charts, allow-
ing for a much richer description of patient characteristics (e.g.,
body mass index). This study is also one of the first to apply
multivariable decomposition analysis to pharmaceutical treat-
ments in a real-world setting; therefore, potential inherent flaws
to this approach remain to be determined. Possible future
applications for decomposition analysis to pharmaceutical treat-
ments could include validation using various types of data for
different diseases and treatments of interest.Conclusions
This study suggests that decomposition analysis could be a
useful tool for examining the source of differences in outcomes
between two pharmaceutical treatments in a real-world setting.
Differences in baseline characteristics (the explained component)
between the two treatment groups contributed most to differ-
ences in HbA1c outcomes at 1 year, whereas differences in
treatment effects (the unexplained component) contributed most
to differences in treatment persistence.
If the validity of decomposition results is confirmed in future
studies, detailed decomposition of the unexplained differences in
outcomes between two drug therapies could serve as a solid
evidence base for practicing personalized medicine, helping
physicians identify patients who may be more likely to respond
to a particular treatment.Acknowledgments
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